Nautilus Biotechnology Inc (NAUT) Stock AnalysisNAUTStock AnalysisNautilus Biotechnology Inc

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprises the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs. Its platform consists of integrated reagents, fluidics, imaging, and ultra-dense nano-array flow cells. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Nautilus Biotechnology Inc is not a strong buy right now due to ongoing financial losses and uncertain revenue growth. The current price is $0.8857, and the company reported a net loss of $14.47 million in Q2 2026, which indicates financial instability. However, the gross margin is high at 92.11%, suggesting potential for profitability if revenue can be sustained. The main risk is the need for additional funding before mid-2027, which could dilute current shareholder value.